KPV

KPV Dermatological & Tissue Overview

KPV initiates profound local changes to the dermal and epidermal architecture, shifting the cellular metabolism exclusively toward structural matrix generation and inflammatory reduction.

Physiochemical Diagnostics

Parameter	Value
Molecular Formula	C17H31N5O4
Molecular Mass	369.5 g/mol
Assay Purity	>99.0%
Appearance	White lyophilized powder

Figure 1: Conceptual Action of KPV

In-Vivo Mechanism Cascade

Detailed transduction pattern yielding the cosmetic or regenerative property:

1. A natural, tripeptide (Lysine-Proline-Valine) fragment of the alpha-MSH hormone.
2. Acts primarily through deep modulation of the NF-kB (Nuclear Factor Kappa B) pathway.
3. Strips inflammatory signaling from the surface of mast cells within the epidermis and gut.
4. Completely shuts down mast cell degranulation, stopping histamine release in its tracks.
5. Inhibits pro-inflammatory cytokines like IL-1, IL-6, and TNF-a directly at the cellular source.

Figure 2: Rate of Structural Deposition

Primary Research Results

• Outcome 1: Leveraged heavily for researching acute relief of psoriasis, eczema, and severe dermatitis.
• Outcome 2: Lacks the melanogenesis (tanning) properties of its parent hormone, preserving baseline skin tone.
• Outcome 3: Considered one of the most potent, targeted anti-inflammatory sequences currently known.

Alpha-MSH Derived Anti-Inflammatory Tripeptide

KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Despite being only three amino acids long, KPV retains the potent anti-inflammatory activity of the full 13-amino acid α-MSH while shedding the melanogenic (tanning) and steroidogenic effects mediated by melanocortin receptors. KPV’s anti-inflammatory mechanism is primarily intracellular: it enters cells and directly inhibits the NF-κB signaling cascade at the level of IκBα phosphorylation, suppressing the master inflammatory transcription program.

1. KPV enters cells through PepT1 transporter-mediated uptake (particularly abundant in intestinal epithelium) and passive diffusion.
2. Intracellularly, KPV inhibits IκB kinase (IKK), preventing phosphorylation and degradation of the IκBα inhibitor protein.
3. With IκBα intact, NF-κB p65/p50 heterodimers remain sequestered in the cytoplasm, unable to translocate to the nucleus.
4. This suppresses transcription of TNF-α, IL-1β, IL-6, IL-8, COX-2, iNOS, and other NF-κB target genes.
5. KPV simultaneously reduces MAPK (p38, ERK, JNK) signaling, providing a second layer of anti-inflammatory control independent of NF-κB.

IBD & Dermatological Research

• Colitis Models: Oral and rectal KPV dramatically reduces colonic inflammation scores, mucosal damage, and myeloperoxidase activity in DSS-induced and TNBS-induced colitis models.
• Oral Bioavailability: The PepT1 transporter in intestinal epithelium actively absorbs KPV, making it one of the few peptides with genuine oral anti-inflammatory efficacy in the gut.
• Atopic Dermatitis: Topical KPV reduces epidermal thickness, inflammatory cell infiltration, and scratching behavior in oxazolone-induced dermatitis models.
• Psoriasis: KPV inhibits keratinocyte hyperproliferation and reduces IL-17/IL-23 axis activation in imiquimod-induced psoriasis models.
• Wound Healing: Anti-inflammatory effects at wound sites reduce excessive granulation tissue formation, promoting cleaner healing with less scar formation.